Generium is the leading Russian biopharmaceutical company. Our company develops and manufactures pharmaceutical products for the treatment of orphan diseases, cancer, multiple sclerosis, growth hormone deficiency, myocardial infarction and strokes as well as tuberculosis diagnostic test.
Generium consists of a
In our R&D center consisting of 5,000 sq. m. of labs, biopharmaceuticals and
Our manufacturing plant is equipped to the highest levels and operates according to Russian and international GMP standards.
Today, seven pharmaceutical products are already available for patients in Russia and CIS countries. These are recombinant Factors VII, VIII and IX for haemophilia treatment,
Generium is the only company in the world, which produces three recombinant coagulation factors (FVII, FVIII and FIX).
In 2014, our skin test for TB detection, Diaskintest, earned the international award Prix Galien for achievements in biotechnology.
There are more than 40 innovative products in the pipeline, including enzymes, monoclonal antibodies and
Our R&D park is located 120 km away from Moscow, where our strategic partners operate as well.